Sampatrilat is an orally active dual vasopeptidase inhibitor, selectively targeting the C-domain of ACE over the N-domain. It is used in research to study cardiovascular and renal physiology, with applications in both in vitro enzyme assays and in vivo models of hypertension and heart failure.
